Search

Your search keyword '"Ye, Byong Duk"' showing total 1,506 results
Start Over Author "Ye, Byong Duk"
1,506 results on '"Ye, Byong Duk"'

7. Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries

Author

Liu, Zhanju, Liu, Ruize, Gao, Han, Jung, Seulgi, Gao, Xiang, Sun, Ruicong, Liu, Xiaoming, Kim, Yongjae, Lee, Ho-Su, Kawai, Yosuke, Nagasaki, Masao, Umeno, Junji, Tokunaga, Katsushi, Kinouchi, Yoshitaka, Masamune, Atsushi, Shi, Wenzhao, Shen, Chengguo, Guo, Zhenglin, Yuan, Kai, Zhu, Shu, Li, Dalin, Liu, Jianjun, Ge, Tian, Cho, Judy, Daly, Mark J., McGovern, Dermot P. B., Ye, Byong Duk, Song, Kyuyoung, Kakuta, Yoichi, Li, Mingsong, and Huang, Hailiang

Published
2023
Full Text
View/download PDF

13. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Author

Abrahamovych, Orest, Afanasieva, Halyna, Aitova, Lilia, Altintas, Engin, Altwegg, Romain, Andreev, Pavel, Aomatsu, Kazuki, Augustyn, Monika, Balestrieri, Paola, Begun, Jakob, Brunatto, Luciana, Bulgheroni, Diego, Bunkova, Elena, Cabello, Mercedes, Cao, Qian, Caprioli, Flavio, Cerqueira, Rute, Chen, Baili, Chen, Chou-Chen, Chen, Chou-Pin, Chiu, Cheng-Tang, Choi, Chang Hwan, Cicala, Michele, Datsenko, Olena, Dewint, Pieter, Domenech, Eugeni, Dutré, Joris, Duvall, George, Fernandez, Juan, Filip, Rafal, Fogel, Ronald, Fowler, Sharyle, Fujii, Toshimitsu, Fukata, Masayuki, Furumoto, Yohei, Gasbarrini, Antonio, Gawdis-Wojnarska, Beata, Gilletta, Cyrielle, Gionchetti, Paolo, Goldin, Eran, Golovchenko, Oleksandr, Gonciarz, Maciej, Gonen, Can, Segura, Gaston Gonzalez, Gridnyev, Oleksii, Gyokeres, Tibor, Hébuterne, Xavier, Hedin, Charlotte, Hellström, Per, Hilmi, Ida Normiha, Horný, Ivo, Horvat, Gyula, Hoshi, Namiko, Hrdlicka, Ludek, Ishihara, Shunji, Ivanishyn, Olha, Jang, Byung Ik, Junior, Odery, Kagaya, Takashi, Kanmura, Shuji, Karakina, Marina, Katsuhiko, Nakai, Kierkus, Jaroslaw, Kim, Hyo Jong, Kim, Tae-Oh, Kim, Young-Ho, Kiss, Gyula G., Klaus, Jochen, Kleczkowski, Dariusz, Klopocka, Maria, Kobayashi, Taku, Kobielusz-Gembala, Iwona, Koo, Ja Seol, Kopon, Adam, Kravchenko, Tetiana, Kudo, Masatoshi, Kwon, Kwang An, Lago, Paula, Laharie, David, Lawrance, Ian, Leszczyszyn, Jaroslaw, Li, Yan, Lukas, Milan, Maaser, Christian, Maemoto, Atsuo, Marusawa, Hiroyuki, McBride, Matthew, Mendu, Shoba, Miheller, Pal, Miyabayashi, Hideharu, Mohl, Wolfgang, Moore, Gregory, Motoya, Satoshi, Murali, Narayanachar, Naem, Mohammed, Nakajima, Koichi, Nakamoto, Yasunari, Nancey, Stéphane, Neto, Joaquim, Onizawa, Michio, Ono, Yohei, Osada, Taro, Osipenko, Marina, Owczarek, Danuta, Patel, Bhaktasharan, Patel, Kamal, Petrova, Elina, Poroshina, Elena, Portela, Francisco, Prystupa, Lyudmyla, Rivero, Monserrat, Roblin, Xavier, Romatowski, Jacek, Rydzewska, Grazyna, Saibeni, Simone, Sakuraba, Hirotake, Samaan, Mark, Schultz, Michael, Schulze, Joerg, Sedghi, Shahriar, Seidler, Ursula, Shin, Sung Jae, Stanislavchuk, Mykola, Stokesberry, David, Suzuki, Takayoshi, Taguchi, Hiroki, Tankova, Lyudmila, Thin, Lena, Tkachev, Alexander, Torrealba, Leyanira, Tsarynna, Nataliia, Tulassay, Zsolt, Ueo, Tetsuya, Valuyskikh, Ekaterina, Vasilevskaya, Olga, Viamonte, Manuel, Wei, Shu-Chen, Weisshof, Roni, Wojcik, Katarzyna, Ye, Byong Duk, Yen, Hsu-Heng, Yoon, Hyuk, Yoshida, Kosuke, Yurkiv, Andriy, Zaha, Osamu, Zhan, Qiang, Peyrin-Biroulet, Laurent, Allegretti, Jessica R., Rubin, David T., Bressler, Brian, Germinaro, Matthew, Huang, Kuan-Hsiang (Gary), Shipitofsky, Nicole, Zhang, Hongyan, Wilson, Rebbecca, Han, Chenglong, Feagan, Brian G., Sandborn, William J., Panés, Julian, Hisamatsu, Tadakazu, Lichtenstein, Gary R., Sands, Bruce E., and Dignass, Axel

Published
2023
Full Text
View/download PDF

14. HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis

Author

Akar, Alaa, Flemming, Cornelius, Felix, Flomm, Flosbach, Markus, Jäger, Julia, Jeromin, Niklas, Jung, Johannes, Ohms, Mareike, Reinshagen, Konrad, Rische, Johann, Sagebiel, Adrian, Sandfort, Deborah, Steinert, Fenja, Tomuschat, Christian, Wesche, Jasmin, Shifteh Abedian, Abraham, Clara, Achkar, Jean-Paul, Ahmad, Tariq, Alberts, Rudi, Alizadeh, Behrooz, Amininejad, Leila, Ananthakrishnan, Ashwin N., Andersen, Vibeke, Anderson, Carl A., Andrews, Jane M., Annese, Vito, Aumais, Guy, Baidoo, Leonard, Baldassano, Robert N., Bampton, Peter A., Barclay, Murray, Barrett, Jeffrey C., Bethge, Johannes, Bewshea, Claire, Bis, Joshua C., Bitton, Alain, BK, Thelma, Boucher, Gabrielle, Brain, Oliver, Brand, Stephan, Brant, Steven R., Cheon, Jae Hee, Chew, Angela, Cho, Judy H., Cleynen, Isabelle, Cohain, Ariella, Cooney, Rachel, Croft, Anthony, Daly, Mark J., D'Amato, Mauro, Danese, Silvio, Daryani, Naser Ebrahim, Datta, Lisa Wu, Degenhardt, Frauke, Denapiene, Goda, Denson, Lee A., Devaney, Kathy L., Dewit, Olivier, D'Inca, Renata, Drummond, Hazel E., Dubinsky, Marla, Duerr, Richard H., Edwards, Cathryn, Ellinghaus, David, Ellul, Pierre, Esaki, Motohiro, Essers, Jonah, Ferguson, Lynnette R., Festen, Eleonora A., Fleshner, Philip, Florin, Tim, Franchimont, Denis, Franke, Andre, Fuyuno, Yuta, Gearry, Richard, Georges, Michel, Gieger, Christian, Glas, Jürgen, Goyette, Philippe, Green, Todd, Griffiths, Anne M., Guthery, Stephen L., Hakonarson, Hakon, Halfvarson, Jonas, Hanigan, Katherine, Haritunians, Talin, Hart, Ailsa, Hawkey, Chris, Hayward, Nicholas K., Hedl, Matija, Henderson, Paul, Hold, Georgina L., Hong, Myhunghee, Hu, Xinli, Huang, Hailiang, Hugot, Jean-Pierre, Hui, Ken Y., Imielinski, Marcin, Jazayeri, Omid, Jonaitis, Laimas, Jostins, Luke, Juyal, Garima, Chandra Juyal, Ramesh, Kalla, Rahul, Karlsen, Tom H., Kennedy, Nicholas A., Khan, Mohammed Azam, Kim, Won Ho, Kitazono, Takanari, Kiudelis, Gediminas, Kubo, Michiaki, Kugathasan, Subra, Kupcinskas, Limas, Lamb, Christopher A., de Lange, Katrina M., Latiano, Anna, Laukens, Debby, Lawrance, Ian C., Lee, James C., Lees, Charlie W., Leja, Marcis, Lewis, Nina, Van Limbergen, Johan, Lionetti, Paolo, Liu, Jimmy Z., Louis, Edouard, Luo, Yang, Mahy, Gillian, Malekzadeh, Masoud Mohammad, Malekzadeh, Reza, Mansfield, John, Marriott, Suzie, Massey, Dunecan, Mathew, Christopher G., Matsui, Toshiyuki, McGovern, Dermot P.B., van der Meulen, Andrea, Midha, Vandana, Milgrom, Raquel, Mirzaei, Samaneh, Mitrovic, Mitja, Montgomery, Grant W., Mowat, Craig, Müller, Christoph, Newman, William G., Ng, Aylwin, Ng, Siew C., Evelyn Ng, Sok Meng, Nikolaus, Susanna, Ning, Kaida, Nöthen, Markus, Oikonomou, Ioannis, Okou, David, Orchard, Timothy R., Palmieri, Orazio, Parkes, Miles, Phillips, Anne, Ponsioen, Cyriel Y., Potocnik, Urõs, Poustchi, Hossein, Prescott, Natalie J., Proctor, Deborah D., Radford-Smith, Graham, Rahier, Jean- Francois, Regueiro, Miguel, Reinisch, Walter, Rieder, Florian, Rioux, John D., Roberts, Rebecca, Rogler, Gerhard, Russell, Richard K., Sanderson, Jeremy D., Sans, Miquel, Satsangi, Jack, Schadt, Eric E., Scharl, Michael, Schembri, John, Schreiber, Stefan, Schumm, L. Philip, Scott, Regan, Seielstad, Mark, Shah, Tejas, Sharma, Yashoda, Silverberg, Mark S., Simmons, Alison, Simms, Lisa A., Singh, Abhey, Skieceviciene, Jurgita, van Sommeren, Suzanne, Song, Kyuyoung, Sood, Ajit, Spain, Sarah L., Steinhart, A. Hillary, Stempak, Joanne M., Stronati, Laura, Sung, Joseph J.Y., Targan, Stephan R., Taylor, Kirstin M., Theatre, Emilie, Torkvist, Leif, Torres, Esther A., Tremelling, Mark, Uhlig, Holm H., Umeno, Junji, Vahedi, Homayon, Vasiliauskas, Eric, Velde, Anje ter, Ventham, Nicholas T., Vermeire, Severine, Verspaget, Hein W., De Vos, Martine, Walters, Thomas, Wang, Kai, Wang, Ming-Hsi, Weersma, Rinse K., Wei, Zhi, Whiteman, David, Wijmenga, Cisca, Wilson, David C., Winkelmann, Juliane, Wong, Sunny H., Xavier, Ramnik J., Yamazaki, Keiko, Yang, Suk-Kyun, Ye, Byong Duk, Zeissig, Sebastian, Zhang, Bin, Zhang, Clarence K., Zhang, Hu, Zhang, Wei, Zhao, Hongyu, Zhao, Zhen Z., Baumdick, Martin E., Niehrs, Annika, Schwerk, Maria, Hinrichs, Ole, Jordan-Paiz, Ana, Padoan, Benedetta, Wegner, Lucy H.M., Schloer, Sebastian, Zecher, Britta F., Malsy, Jakob, Joshi, Vinita R., Illig, Christin, Schröder-Schwarz, Jennifer, Möller, Kimberly J., Martin, Maureen P., Yuki, Yuko, Ozawa, Mikki, Sauter, Jürgen, Schmidt, Alexander H., Perez, Daniel, Giannou, Anastasios D., Carrington, Mary, Davis, Randall S., Schumacher, Udo, Sauter, Guido, Huber, Samuel, Puelles, Victor G., Melling, Nathaniel, Altfeld, Marcus, and Bunders, Madeleine J.

Published
2023
Full Text
View/download PDF

17. Burden of Herpes Zoster in Individuals With Chronic Conditions in the Republic of Korea: A Nationwide Population-Based Database Study.

Author

Chen, Jing, Shin, Ju-Young, Bea, Sungho, Ye, Byong Duk, Lee, Dong-Gun, Kim, Hyungwoo, Choi, Won Suk, and Shantakumar, Sumitra

Subjects
NATIONAL health insurance, HERPES zoster, CHRONIC obstructive pulmonary disease, CHRONIC kidney failure, AGE groups
Abstract

Background Chronic conditions (CCs) may increase the risk of herpes zoster (HZ) infection, leading to a greater healthcare burden in these individuals compared to those without CCs. It is therefore clinically important to quantify HZ disease burden in individuals with and without CCs, given the rapidly aging population in the Republic of Korea (ROK). Methods This retrospective cohort study examines the trends in incidence rates (IRs) and incidence rate ratios (IRRs) in individuals aged ≥18 years with CCs, using the National Health Insurance Service National Sample Cohort (NHIS-NSC) database from 2010 to 2019. These patients were stratified by age group, sex, HZ complications, and CCs. The annual average number of HZ patients, IRs, and IRRs were calculated for individuals with and without CCs. Results In total, 729 347 patients with HZ were eligible for the study. HZ IRs were highest in patients with diabetes, followed by chronic obstructive pulmonary disease, chronic kidney disease, asthma, and chronic liver disease, with HZ IRRs following a similar trend. Overall, HZ IRs generally increased with age, typically peaking at 60–64 or 65–69 years, and were similar for females and males. HZ IRs were highest among patients without complications, followed by HZ with other, cutaneous, ocular, and neurologic complications across all CCs. For each of the CCs, HZ IRs were consistently higher than those of the non-CC population regardless of sex. Conclusions The findings of this study reiterate the importance of HZ prevention for healthy aging, especially for CC populations at increased risk of HZ in the ROK. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Author

Aguilar, Humberto, Ahmad, Tariq, Akriviadis, Evangelos, Aldeguer Mante, Xavier, Allez, Matthieu, Altorjay, Istvan, Ananthakrishnan, Ashwin, Andersen, Vibeke, Andreu Garcia, Montserrat, Armuzzi, Alessandro, Aumais, Guy, Avni-Biron, Irit, Axler, Jeffrey, Ayub, Kamran, Jr., Baert, Filip, Bafutto, Mauro, Bamias, George, Bassan, Isaac, Baum, Curtis, Beaugerie, Laurent, Behm, Brian, Bekal, Pradeep, Bennett, Michael, Bermejo San Jose, Fernando, Bernstein, Charles, Bettenworth, Dominik, Bhaskar, Sudhir, Biancone, Livia, Bilir, Bahri, Blaeker, Michael, Bloom, Stuart, Bohman, Verle, Jr., Bosques Padilla, Francisco Javier, Bossuyt, Peter, Bouhnik, Yoram, Bouma, Gerd, Bourdages, Raymond, Brand, Stephan, Bressler, Brian, Brückner, Markus, Buening, Carsten, Carbonnel, Franck, Caves, Thomas, Chapman, Jonathon, Cheon, Jae Hee, Chiba, Naoki, Chioncel, Camelia, Christodoulou, Dimitrios, Clodi, Martin, Cohen, Albert, Corazza, Gino Roberto, Corlin, Richard, Cosintino, Rocco, Cummings, Fraser, Dalal, Robin, Danese, Silvio, De Maeyer, Marc, De Magalhães Francesconi, Carlos Fernando, De Silva, Aminda, Debinski, Henry, Desreumaux, Pierre, Dewit, Olivier, D'Haens, Geert, Di Felice Boratto, Sandra, Ding, John Nik, Dixon, Tyler, Dryden, Gerald, Jr., Du Vall, George Aaron, Ebert, Matthias, Echarri Piudo, Ana, Ehehalt, Robert, Elkhashab, Magdy, Ennis, Craig, Etzel, Jason, Fallingborg, Jan, Feagan, Brian, Fejes, Roland, Ferraz de Campos Mazo, Daniel, Ferreira de Almeida Borges, Valéria, Fischer, Andreas, Fixelle, Alan, Fleisher, Mark, Fowler, Sharyle, Freilich, Bradley, Friedenberg, Keith, Fries, Walter, Fulop, Csaba, Fumery, Mathurin, Fuster, Sergio, G Kiss, Gyula, Garcia Lopez, Santiago, Gassner, Sonja, Gill, Kanwar, Gilletta de Saint Joseph, Cyrielle, Ginsburg, Philip, Gionchetti, Paolo, Goldin, Eran, Goldis, Adrian-Eugen, Gomez Jaramillo, Hector Alejandro, Gonciarz, Maciej, Gordon, Glenn, Green, Daniel, Grimaud, Jean-Charles, Guajardo Rodriguez, Rogelio, Gurzo, Zoltan, Gutierrez, Alexandra, Gyökeres, Tibor, Hahm, Ki Baik, Hanauer, Stephen, Hanson, John, Harlan III, William, Hasselblatt, Peter, Hayee, Buhussain, Hebuterne, Xavier, Hendy, Peter, Heyman, Melvin, Higgins, Peter, Hilal, Raouf, Hindryckx, Pieter, Hoentjen, Frank, Hoffmann, Peter, Holtkamp-Endemann, Frank, Holtmann, Gerald, Horvat, Gyula, Howaldt, Stefanie, Huber, Samuel, Ibegbu, Ikechukwu, Iborra Colomino, Maria Isabel, Irving, Peter, Isaacs, Kim, Jagarlamudi, Kiran, Jain, Rajesh, Jankiel Miszputen, Sender, Jansen, Jeroen, Jones, Jennifer, Juillerat, Pascal, Karagiannis, John, Karyotakis, Nicholas, Kaser, Arthur, Katz, Lior, Katz, Seymour, Katz, Leo, Kaur, Nirmal, Kazenaite, Edita, Khanna, Reena, Khurana, Sunil, Kim, Joo Sung, Kim, Young-Ho, Kim, Sung Kook, Kim, Dongwoo, Klaus, Jochen, Kleczkowski, Dariusz, Kohout, Pavel, Korczowski, Bartosz, Kouklakis, Georgios, Koutroubakis, Ioannis, Krause, Richard, Kristof, Tunde, Kronborg, Ian, Krummenerl, Annette, Kupcinskas, Limas, Laborda Molteni, Jorge, Laharie, David, Lahat-zok, Adi, Lee, Jonghun, Lee, Kang-Moon, Leong, Rupert, Levine, Henry, Limdi, Jimmy, Lindsay, James, Lodhia, Nilesh, Loftus, Edward, Longman, Randy, Lopez Serrano, Pilar, Louis, Edouard, Louzada Pereira, Maria Helena, Lowe, John, Lueth, Stefan, Lukas, Milan, Maconi, Giovanni, Macrae, Finlay, Madi-Szabo, Laszlo, Mahadevan-Velayos, Uma, Malluta, Everson Fernando, Mana, Fazia, Mannon, Peter, Mantzaris, Gerasimos, Marin Jimenez, Ignacio, Martin Arranz, Maria Dolores, Mateescu, Radu-Bogdan, Mazzoleni, Felipe, Meder, Agnieszka, Melzer, Ehud, Mertens, Jessica, Mimidis, Konstantinos, Mitchell, Brent, Molnar, Tamas, Moore, Gregory, Morales Garza, Luis Alonso, Mountifield, Reme, Muls, Vinciane, Murray, Charles, Nagy, Bela, Neurath, Markus, Nguyen, Augustin, Panaccione, Remo, Pandak, William, Panes Diaz, Julian, Park, Jihye, Pastorelli, Luca, Patel, Bhaktasharan, Peck-Radosavljevic, Markus, Pecsi, Gyula, Peerani, Farhad, Perez Gisbert, Javier, Pesta, Martin, Petryka, Robert, Peyrin-Biroulet, Laurent, Phillips, Raymond, Pierik, Marieke, Pratha, Vijayalakshmi, Prochazka, Vlastimil, Racz, Istvan, Radford-Smith, Graham, Ramos Castañeda, Daniel, Ramos Júnior, Odery, Regula, Jaroslaw, Reimund, Jean-Marie, Robbins, Bryan, Roblin, Xavier, Rogai, Francesca, Rogler, Gerhard, Rozciecha, Jerzy, Rubin, David, Ruiz Flores, Azalia Yuriria, Rupinski, Maciej, Rydzewska, Grazyna, Saha, Sumona, Saibeni, Simone, Salamon, Agnes, Sallo, Zoltan, Salzberg, Bruce, Samuel, Douglas, Samuel, Sunil, Sandborn, William, Savarino, Edoardo Vincenzo, Schirbel, Anja, Schnabel, Robert, Schreiber, Stefan, Scott, John, Sedghi, Shahriar, Seibold, Frank, Seidelin, Jakob, Seidler, Ursula, Shaban, Ahmad, Shafran, Ira, Sheikh, Aasim, Sherman, Alex, Shirin, Haim, Smolinski, Patryk, Song, Geun Am, Soufleris, Konstantinos, Speight, Alexander, Staessen, Dirk, Stallmach, Andreas, Staun, Michael, Stein, Daniel, Steinhart, Hillary, Stifft, Jonathas, Stokesberry, David, Sturm, Andreas, Sultan, Keith, Szekely, Gyorgy, Tagore, Kuldeep, Tanno, Hugo, Thin, Lena, Thiwan, Syed, Thomas, Carlton, Tichy, Michal, Toth, Gabor Tamas, Tulassay, Zsolt, Ulbrych, Jan, Valentine, John, Varga, Marta, Vasconcellos, Eduardo, Vaughn, Byron, Velasco, Brenda, Velazquez, Francisco, Vermeire, Severine, Villa, Erica, Vincze, Aron, Vogelsang, Harald, Volfova, Miroslava, Vuitton, Lucine, Vyhnalek, Petr, Wahab, Peter, Walldorf, Jens, Waterman, Mattitiahu, Weber, John, Weiss, L. Michael, Wiechowska-Kozlowska, Anna, Wiesner, Elise, Witthoeft, Thomas, Wohlman, Robert, Wozniak-Stolarska, Barbara, Yacyshyn, Bruce, Ye, Byong-Duk, Younes, Ziad, Yukie Sassaki, Lígia, Zaltman, Cyrla, Zeuzem, Stefan, Hart, Ailsa, Long, Millie, Loftus, Edward V, Jr, Ostad-Saffari, Elham, Scalori, Astrid, Oh, Young S, Tole, Swati, Chai, Akiko, Pulley, Jennifer, Lacey, Stuart, and Sandborn, William J

Published
2022
Full Text
View/download PDF

19. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

Author

Aboo, Nazimuddin, Ahmad, Tariq, Aldeguer Mante, Xavier, Allez, Matthieu, Almer, Sven, Altwegg, Romain, Andreu Garcia, Montserrat, Arasaradnam, Ramesh, Ardizzone, Sandro, Armuzzi, Alessandro, Arnott, Ian, Aumais, Guy, Avni-Biron, Irit, Barrow, Peter, Beales, Ian, Bermejo San Jose, Fernando, Bezuidenhout, Abraham, Biancone, Livia, Blaeker, Michael, Bloom, Stuart, Bokemeyer, Bernd, Bossa, Fabrizio, Bossuyt, Peter, Bouguen, Guillaume, Bouhnik, Yoram, Bouma, Gerd, Bourdages, Raymond, Bourreille, Arnaud, Boustiere, Christian, Brabec, Tomas, Brand, Stephan, Buening, Carsten, Buisson, Anthony, Cadiot, Guillaume, Calvet Calvo, Xavier, Carbonnel, Franck, Carpio, Daniel, Cheon, Jae Hee, Chiba, Naoki, Chioncel, Camelia, Cimpoeru, Nicoleta-Claudia, Clodi, Martin, Corazza, Gino Roberto, Cosintino, Rocco, Cotter, Jose, Creed, Thomas, Cummings, Fraser, Danese, Silvio, de' Angelis, Gian Luigi, De Maeyer, Marc, Desai, Milind, Desilets, Etienne, Desreumaux, Pierre, Dewit, Olivier, D'Haens, Geert, Dinter, Johanna, Dobru, Ecaterina Daniela, Douda, Tomas, Dumitrascu, Dan Lucian, Ebert, Matthias, Echarri Piudo, Ana, Elkhashab, Magdy, Eun, Chang Soo, Feagan, Brian, Fejes, Roland, Fidalgo, Catarina, Fishman, Sigal, Flourié, Bernard, Fowler, Sharyle, Fries, Walter, Fulop, Csaba, Fumery, Mathurin, G Kiss, Gyula, Gassner, Sonja, Gaya, Daniel, Germanà, Bastianello, Gheorghe, Liliana Simona, Gilletta de Saint Joseph, Cyrielle, Gionchetti, Paolo, Goldis, Adrian-Eugen, Gonçalves, Raquel, Grimaud, Jean-Charles, Gyökeres, Tibor, Hagege, Herve, Haidar, Andrei, Hartmann, Heinz, Hasselblatt, Peter, Hayee, Buhussain, Hebuterne, Xavier, Hellström, Per, Hindryckx, Pieter, Hlavova, Helena, Hoentjen, Frank, Howaldt, Stefanie, Hrdlicka, Ludek, Huh, Kyu Chan, Iborra Colomino, Maria Isabel, Ionita-Radu, Florentina, Irving, Peter, Jahnsen, Jørgen, Jang, ByungIk, Jansen, Jeroen, Jeon, Seong Woo, Jover Martinez, Rodrigo, Juillerat, Pascal, Karlén, Per, Kaser, Arthur, Keil, Radan, Kejariwal, Deepak, Keret, Dan, Khanna, Reena, Kim, Dongwoo, Kim, Duk Hwan, Kim, Hyo-Jong, Kim, Hyun-Soo, Kim, Joo Sung, Kim, Kueongok, Kim, Kyung-Jo, Kim, Sung Kook, Kim, Young-Ho, Klaus, Jochen, Kohn, Anna, Kojecky, Vladimir, Koo, Ja Seol, Kozak, Robert, Kremer, Milan, Kristof, Tunde, Kruger, Frederik, Laharie, David, Lahat-zok, Adi, Landa, Evgeny, Lee, Jonghun, Lee, Kang-Moon, Lee, Kook Lae, Lee, YooJin, Lenze, Frank, Lim, Wee Chian, Limdi, Jimmy, Lindsay, James, Lopez Serrano, Pilar, Louis, Edouard, Lueth, Stefan, Lukas, Milan, Maconi, Giovanni, Mana, Fazia, Mann, Steven, Mansfield, John, Marchi, Santino, Marino, Marco, Marshall, John, Martin Arranz, Maria Dolores, Mateescu, Radu-Bogdan, McLaughlin, John, McLaughlin, Simon, Melzer, Ehud, Mertens, Jessica, Mitrut, Paul, Molnar, Tamas, Muls, Vinciane, Munuswamy, Pushpakaran, Murray, Charles, Naftali, Timna, Naidoo, Visvakuren, Nanabhay, Yusuf, Negreanu, Lucian, Nguyen, Augustin, Ochsenkuehn, Thomas, Orlando, Ambrogio, Panaccione, Remo, Panes Diaz, Julian, Paritsky, Maya, Park, Dong Il, Park, Jihye, Pastorelli, Luca, Peck-Radosavljevic, Markus, Peerani, Farhad, Perez Gisbert, Javier, Peyrin-Biroulet, Laurent, Picon, Laurence, Pierik, Marieke, Ponich, Terry, Portela, Francisco, Prins, Maartens Jeroen, Racz, Istvan, Rahman, Khan Fareed, Reimund, Jean-Marie, Reinshagen, Max, Roblin, Xavier, Rocca, Rodolfo, Rogai, Francesca, Rogler, Gerhard, Salamon, Agnes, Salazar, Ennaliza, Sallo, Zoltan, Samuel, Sunil, Sans Cuffi, Miquel de los Santos, Savarino, Edoardo Vincenzo, Savarino, Vincenzo, Savoye, Guillaume, Schreiber, Stefan, Seicean, Andrada, Selinger, Christian, Serra, David Martins, Shim, Hang Hock, Shin, SungJae, Siegmund, Britta, Siffledeen, Jesse, Simmonds, Wayne, Smid, Jan, Sollano, Jose, Song, Geun Am, Speight, Alexander, Sporea, Ioan, Staessen, Dirk, Stancu, George, Steel, Alan, Stepek, David, Stoica, Victor, Sturm, Andreas, Szekely, Gyorgy, Tan, Teck Kiang, Taxonera Samso, Carlos, Thomson, John, Tichy, Michal, Toth, Gabor Tamas, Tulassay, Zsolt, Vangeli, Marcello, Varga, Marta, Vieira, Ana, Viennot, Stephanie, Villa, Erica, Vitek, Petr, Vogelsang, Harald, Vyhnalek, Petr, Wahab, Peter, Walldorf, Jens, Ye, Byong Duk, Ziady, Christopher, Colombel, Jean-Frederic, Gisbert, Javier P, Hayee, Bu'hussain, Reinisch, Walter, Tyrrell, Helen, Oh, Young S, Tole, Swati, Chai, Akiko, Chamberlain-James, Kirsten, and Tang, Meina Tao

Published
2022
Full Text
View/download PDF

20. Immunochip Meta-Analysis of Inflammatory Bowel Disease Identifies Three Novel Loci and Four Novel Associations in Previously Reported Loci

Author

Hong, Myunghee, Ye, Byong Duk, Yang, Suk-Kyun, Jung, Seulgi, Lee, Ho-Su, Kim, Byoung Mok, Bin Lee, Soo, Hong, Jeonghoon, Baek, Jiwon, Park, Sang Hyoung, Han, Buhm, Li, Yi, Liu, Wenting, Haritunians, Talin, Taylor, Kent D, Rotter, Jerome I, Bang, So-Young, Kim, Tae-Hwan, McGovern, Dermot PB, Liu, Jianjun, and Song, Kyuyoung

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Inflammatory Bowel Disease, Digestive Diseases, Autoimmune Disease, Genetics, Crohn's Disease, Aetiology, 2.1 Biological and endogenous factors, Inflammatory and immune system, Oral and gastrointestinal, Asian People, Genetic Loci, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Inflammatory Bowel Diseases, Intracellular Signaling Peptides and Proteins, Membrane Proteins, Myosins, NF-KappaB Inhibitor alpha, Nerve Tissue Proteins, Nuclear Proteins, Phosphoproteins, Polymorphism, Single Nucleotide, Proteasome Endopeptidase Complex, Protein Phosphatase 2, Protein Serine-Threonine Kinases, Repressor Proteins, Republic of Korea, Ribonuclease P, Tetraspanins, Trans-Activators, White People, Inflammatory bowel disease, meta-analysis, trans-ethnic, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background and aimsRecent meta-analysis of genome-wide association studies have identified over 241 inflammatory bowel disease susceptibility loci. However, the known variants only account for a fraction of inflammatory bowel disease heritability. To identify additional susceptibility loci, we performed a trans-ethnic meta-analysis as well as an Asian-specific meta-analysis, using all published Immunochip association results of inflammatory bowel disease.MethodsAn inverse-variance fixed-effects meta-analysis was carried out across Korean and East Asian Immunochip datasets of 4156 cases and 4904 controls [Asian ancestry]. A trans-ethnic meta-analysis of inflammatory bowel disease was performed together with the European datasets of 38 155 cases and 48 485 controls genotyped on the immunochip using a Bayesian approach, Meta-Analysis of Trans-ethnic Association studies [MANTRA].ResultsWe identified seven novel associations, including three novel susceptibility loci at MYO10-BASP1, PPP2R3C/KIAA0391/PSMA6/NFKB1A and LRRK1 as well as four novel secondary associations within previously known loci at NCF4, TSPAN32, CIITA and VANGL2. The new loci further implicate alterations in B cell biology in Crohn's disease pathogenesis. The effects of five loci were universal across European and Asian ancestries, whereas the NCF4 and CIITA loci showed significant heterogeneity between European and East Asian populations. In addition, 103 previously known IBD loci showed supporting evidence of association with nominal significance [p < 0.05] in Asians.ConclusionsOur findings of new loci not previously associated with IBD support the importance of studying inflammatory bowel disease genetics in diverse populations.

Published
2018

22. Ten missteps in the management of inflammatory bowel disease in Asia: An expert report by the Asian Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease

Author

Ahuja, Vineet, primary, Hilmi, Ida, additional, Ye, Byong Duk, additional, Ling, Khoon Lin, additional, Ng, Siew C., additional, Leong, Rupert W., additional, Kumar, Peeyush, additional, Khoo, Xin Hui, additional, Makharia, Govind K., additional, Sollano, Jose, additional, Pisespongsa, Pises, additional, Mustaffa, Nazri, additional, Banerjee, Rupa, additional, Leow, Alex Hwong‐Ruey, additional, Raja Ali, Raja Affendi, additional, Chuah, Sai Wei, additional, Palaniappan, Shanthi, additional, Ooi, Choon Jin, additional, and Leung, Wai K., additional

Published
2024
Full Text
View/download PDF

25. Characteristics, clinical outcomes, and prognostic factors of colorectal cancer in patients with Crohn's disease: American versus Korean tertiary referral center perspectives.

Author

Suttichaimongkol, Tanita, Hwang, Sung Wook, Coelho-Prabhu, Nayantara, Kisiel, John B., Ye, Byong Duk, Yang, Suk-Kyun, Loftus Jr., Edward V., and Park, Sang Hyoung

Subjects
CROHN'S disease, CANCER prognosis, ELECTRONIC health records, PROGNOSIS, BODY mass index, CHOLANGITIS
Abstract

Background: Crohn's disease (CD) exhibits variability in colorectal cancer (CRC) incidence and prognostic factors due to diverse clinical and behavioral characteristics, presenting inconsistencies between Western and Eastern patients. Objectives: This study compared clinical characteristics between CD patients with CRC from the US and Korean tertiary referral centers and defined the prognostic factors related to mortality. Design: Retrospective study. Methods: We reviewed the electronic medical records of 236 adult CD patients with colorectal adenocarcinoma evaluated at Mayo Clinic Rochester, Florida, or Arizona (N = 200) and Asan Medical Center in Korea (N = 36) between January 1989 and August 2022. Results: Asan patients had a younger age, shorter CD duration, more colonic involvement (L2 plus L3), penetrating behavior, perianal fistula, and shorter biological treatment duration before CRC diagnosis than Mayo patients. Furthermore, despite significant differences in body mass index, smoking status, primary sclerosing cholangitis, immunomodulators, CRC diagnosis period, clinical presentation, CRC location, surgery, and some histopathological details between the two groups, overall survival was not statistically different (p value, 0.29, log-rank test). Advanced age (adjusted hazard ratio (aHR), 1.03 per year; 95% confidence interval (CI), 1.01–1.04; p value, <0.01), unresectable CRC (aHR, 5.02; 95% CI, 2.49–10.12; p value, <0.01), and advanced CRC stage (aHR, 1.45 per stage; 95% CI, 1.07–1.97; p value, 0.02) were significantly associated with increased risk of death. CD remission at CRC diagnosis (aHR, 0.26; 95% CI, 0.08–0.91; p value, 0.04), CRC diagnosis period of 2011–2022 (aHR relative to 1989–2000, 0.46; 95% CI, 0.25–0.87; p value, 0.02), and CRC diagnosis by surveillance (aHR, 0.56; 95% CI, 0.32–0.98; p value, 0.04) were significantly associated with decreased risk of death. Conclusion: Notably, some clinical features of CD with CRC differed between Asan and Mayo patients; however, overall survival was not different. CD remission, CRC surveillance, and more recent diagnosis of CRC were associated with a reduced risk of death. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐TNF therapy: A nationwide population‐based study.

Author

Seo, Jeongkuk, Kim, Seonok, Hong, Seung Wook, Hwang, Sung Wook, Park, Sang Hyoung, Yang, Dong‐Hoon, Byeon, Jeong‐Sik, Myung, Seung‐Jae, Yang, Suk‐Kyun, Kim, Ye‐Jee, and Ye, Byong Duk

Subjects
CROHN'S disease, DISEASE risk factors, NATIONAL health insurance, ULCERATIVE colitis, DISEASE relapse, INFLAMMATORY bowel diseases
Abstract

Summary: Background: The impact of continuing or stopping 5‐aminosalicylates (5‐ASA) after commencing anti‐tumour necrosis factor (anti‐TNF) therapy in patients with inflammatory bowel disease (IBD) remains unclear. Aims: To compare the outcomes of patients with IBD who stopped or continued 5‐ASA after starting anti‐TNF therapy. Methods: We analysed data from the Korean National Health Insurance claims database between 2007 and 2020. We compared the clinical outcomes of patients who stopped or continued 5‐ASA within 90 days of anti‐TNF initiation. The primary outcome was any adverse clinical event defined as a composite of new corticosteroid use, IBD‐related hospitalisation, or intestinal surgery. Results: Among 7442 patients included for analysis (4479 [60.2%] with Crohn's disease [CD] and 2963 [39.8%] with ulcerative colitis [UC]), 1037 (13.9%) discontinued 5‐ASA within 90 days of starting anti‐TNF therapy. During a median 4.3‐year follow‐up, discontinuation of 5‐ASA was not associated with an increased risk of adverse clinical events (adjusted hazard ratio 1.01, 95% confidence interval 0.93–1.10). The cumulative incidence of each adverse clinical event and the composite outcome were not significantly different between groups (all, p > 0.05). Additionally, separate analyses in CD and UC cohorts revealed no differences in adverse clinical outcomes between the 5‐ASA continuation and discontinuation groups. Subgroup analyses by presumed risk factors for disease relapse showed no significant differences in the risk of adverse events between groups. Conclusions: In this nationwide population‐based study, discontinuing 5‐ASA after starting anti‐TNF therapy was not associated with an increased risk of adverse events in patients with IBD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Safety of Biologics and Small Molecules for Inflammatory Bowel Diseases in Organ Transplant Recipients

Author

Kim, Ga Hee, primary, Kim, Minjun, additional, Kim, Kyuwon, additional, Park, Jung-Bin, additional, Baek, Ji Eun, additional, Bae, June Hwa, additional, Hong, Seung Wook, additional, Hwang, Sung Wook, additional, Yang, Dong-Hoon, additional, Ye, Byong Duk, additional, Byeon, Jeong-Sik, additional, Myung, Seung-Jae, additional, Yang, Suk-Kyun, additional, and Park, Sang Hyoung, additional

Published
2024
Full Text
View/download PDF

35. Immunochip Analysis Identification of 6 Additional Susceptibility Loci for Crohn's Disease in Koreans

Author

Yang, Suk-Kyun, Hong, Myunghee, Choi, Hyunchul, Zhao, Wanting, Jung, Yusun, Haritunians, Talin, Ye, Byong Duk, Kim, Kyung-Jo, Park, Sang Hyoung, Lee, Inchul, Kim, Won Ho, Cheon, Jae Hee, Kim, Young-Ho, Jang, Byung Ik, Kim, Hyun-Soo, Choi, Jai Hyun, Koo, Ja Seol, Lee, Ji Hyun, Jung, Sung-Ae, Shin, Hyoung Doo, Kang, Daehee, Youn, Hee-Shang, Taylor, Kent D, Rotter, Jerome I, Liu, Jianjun, McGovern, Dermot PB, and Song, Kyuyoung

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Digestive Diseases, Inflammatory Bowel Disease, Human Genome, Autoimmune Disease, Crohn's Disease, Genetics, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Adolescent, Adult, Asian People, Biomarkers, Case-Control Studies, Cohort Studies, Crohn Disease, Female, Follow-Up Studies, Genetic Loci, Genetic Predisposition to Disease, Genome-Wide Association Study, Genotype, Humans, Male, Odds Ratio, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Prognosis, Young Adult, Crohn's disease, genetics, ImmunoChip, Korean, Gastroenterology & Hepatology, Clinical sciences
Abstract

BackgroundCrohn's disease (CD) is an intractable inflammatory bowel disease of unknown cause. Recent genome-wide association studies of CD in Korean and Japanese populations suggested marginal sharing of susceptibility loci between Caucasian and Asian populations. As the 7 identified loci altogether explain 5.31% of the risk for CD, the objective of this study was to identify additional CD susceptibility loci in the Korean population.MethodsUsing the ImmunoChip custom single-nucleotide polymorphism array designed for dense genotyping of 186 loci identified through GWAS, we analyzed 722 individuals with CD and 461 controls for 96,048 SNP markers in the discovery stage, followed by validation in an additional 948 affected individuals and 977 controls.ResultsWe confirmed 6 previously reported loci in Caucasian: GPR35 at 2q37 (rs3749172; P = 5.30 × 10, odds ratio [OR] = 1.45), ZNF365 at 10q21 (rs224143; P = 2.20 × 10, OR = 1.38), ZMIZ1 at 10q22 (rs1250569; P = 3.05 × 10, OR = 1.30), NKX2-3 at 10q24 (rs4409764; P = 7.93 × 10, OR = 1.32), PTPN2 at 18p11 (rs514000; P = 9.00 × 10, OR = 1.33), and USP25 at 21q11 (rs2823256; P = 2.49 × 10, OR = 1.35), bringing the number of known CD loci (including 3 in the HLA) in Koreans to 15. The 6 additional loci increased the total genetic variance for CD risk from 5.31% to 7.27% in Koreans.ConclusionsAlthough the different genetic backgrounds of CD between Asian and Western countries has been well established for the major susceptibility genes, our findings of overlapping associations offer new insights into the genetic architecture of CD.

Published
2015

47. Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study.

Author

Kim, Kyuwon, Park, Jae Jun, Yoon, Hyuk, Lee, Jun, Kim, Kyeong Ok, Kim, Eun Sun, Kim, Su Young, Boo, Sun‐Jin, Jung, Yunho, Yoo, Jun Hwan, Hwang, Sung Wook, Park, Sang Hyoung, Yang, Suk‐Kyun, and Ye, Byong Duk

Subjects
CLINICAL decision support systems, INFLAMMATORY bowel diseases, CROHN'S disease, RECEIVER operating characteristic curves, CLINICAL medicine
Abstract

Summary: Background/Aim: We aimed to validate clinical decision support tools (CDSTs) to predict real‐life effectiveness of vedolizumab (VDZ) in patients with inflammatory bowel disease. Methods: We retrospectively enrolled patients with Crohn's disease (CD) or ulcerative colitis (UC) treated with VDZ at 10 tertiary referral centres in Korea between January 2017 and November 2021. We assessed clinical remission (CREM) and response (CRES), corticosteroid‐free clinical remission (CSF‐CREM) and response (CSF‐CRES), biochemical response based on C‐reactive protein (BioRES[CRP]) and faecal calprotectin (BioRES[FC]), endoscopic healing (EH), and the need to optimise or switch drugs based on CDST‐defined response groups. Additionally, the area under the receiver operating characteristics curve (AUC) for the CDSTs was calculated. Results: We included 143 patients with CD and 219 with UC. We observed incremental trends on CSF‐CRES at week 14 (W14) (ptrend = 0.004) and decreasing trends for the need to optimise or switch drugs (ptrend = 0.016) in CD from the low to high probability groups. Except for CSF‐CREM at W54, we noticed incremental trends for all clinical responses at W14, W26 and W54 (ptrend <0.001) in UC. W26 and W54 BioRES[CRP] and W14 EH also showed increasing trends (ptrend <0.05) in UC. With increasing probabilities of response, drug optimisation or switching was less frequently required in UC (ptrend = 0.013). With 26 points cut‐off, CDSTs effectively identified W14 CSF‐CRES, W26 BioRES[CRP], BioRES[FC] and W54 BioRES[CRP] in UC, all with AUCs >0.600, whereas CDSTs showed poor accuracy in CD. Conclusions: CDSTs for VDZ had acceptable accuracy in predicting effectiveness outcomes including clinical and biochemical outcomes in UC. However, their utility in CD was limited. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Fecal Calprotectin in Patients with Crohn's Disease: A Study Based on the History of Bowel Resection and Location of Disease.

Author

Seo, Jeongkuk, Song, Subin, Shin, Seung Hwan, Park, Suhyun, Hong, Seung Wook, Park, Sang Hyoung, Yang, Dong-Hoon, Ye, Byong Duk, Byeon, Jeong-Sik, Myung, Seung-Jae, Yang, Suk-Kyun, and Hwang, Sung Wook

Subjects
CROHN'S disease, INTESTINAL diseases, CALPROTECTIN, SMALL intestine, MAGNETIC resonance
Abstract

Fecal calprotectin (FC) is commonly used to assess Crohn's disease (CD) activity. However, standardized cut-off values accounting for bowel resection history and disease location are lacking. In this study, we analyzed data from patients with CD who underwent magnetic resonance enterography, ileocolonoscopy, and FC measurements from January 2017 to December 2018. In 267 cases from 254 patients, the FC levels in the 'operated' patients were higher when the disease was active compared with those who were in the remission group (178 vs. 54.7 μg/g; p < 0.001), and similar findings were obtained for the 'non-operated' patients (449.5 vs. 40.95 μg/g; p < 0.001). The FC levels differed significantly according to the location of inflammation, with lower levels in the small bowel compared to those in the colon. The FC cut-off levels of 70.8 μg/g and 142.0 μg/g were considered optimal for predicting active disease for operated and non-operated patients, respectively. The corresponding FC cut-off levels of 70.8 μg/g and 65.0 μg/g were observed for patients with disease only in the small bowel. In conclusion, different FC cut-off values would be applicable to patients with CD based on their bowel resection history and disease location. Tight control with a lower FC target may benefit those with a history of bowel resection or small-bowel-only disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Author

Peyrin-Biroulet, Laurent, primary, Allegretti, Jessica R., additional, Rubin, David T., additional, Bressler, Brian, additional, Germinaro, Matthew, additional, Huang, Kuan-Hsiang (Gary), additional, Shipitofsky, Nicole, additional, Zhang, Hongyan, additional, Wilson, Rebbecca, additional, Han, Chenglong, additional, Feagan, Brian G., additional, Sandborn, William J., additional, Panés, Julian, additional, Hisamatsu, Tadakazu, additional, Lichtenstein, Gary R., additional, Sands, Bruce E., additional, Dignass, Axel, additional, Abrahamovych, Orest, additional, Afanasieva, Halyna, additional, Aitova, Lilia, additional, Altintas, Engin, additional, Altwegg, Romain, additional, Andreev, Pavel, additional, Aomatsu, Kazuki, additional, Augustyn, Monika, additional, Balestrieri, Paola, additional, Begun, Jakob, additional, Brunatto, Luciana, additional, Bulgheroni, Diego, additional, Bunkova, Elena, additional, Cabello, Mercedes, additional, Cao, Qian, additional, Caprioli, Flavio, additional, Cerqueira, Rute, additional, Chen, Baili, additional, Chen, Chou-Chen, additional, Chen, Chou-Pin, additional, Chiu, Cheng-Tang, additional, Choi, Chang Hwan, additional, Cicala, Michele, additional, Datsenko, Olena, additional, Dewint, Pieter, additional, Domenech, Eugeni, additional, Dutré, Joris, additional, Duvall, George, additional, Fernandez, Juan, additional, Filip, Rafal, additional, Fogel, Ronald, additional, Fowler, Sharyle, additional, Fujii, Toshimitsu, additional, Fukata, Masayuki, additional, Furumoto, Yohei, additional, Gasbarrini, Antonio, additional, Gawdis-Wojnarska, Beata, additional, Gilletta, Cyrielle, additional, Gionchetti, Paolo, additional, Goldin, Eran, additional, Golovchenko, Oleksandr, additional, Gonciarz, Maciej, additional, Gonen, Can, additional, Segura, Gaston Gonzalez, additional, Gridnyev, Oleksii, additional, Gyokeres, Tibor, additional, Hébuterne, Xavier, additional, Hedin, Charlotte, additional, Hellström, Per, additional, Hilmi, Ida Normiha, additional, Horný, Ivo, additional, Horvat, Gyula, additional, Hoshi, Namiko, additional, Hrdlicka, Ludek, additional, Ishihara, Shunji, additional, Ivanishyn, Olha, additional, Jang, Byung Ik, additional, Junior, Odery, additional, Kagaya, Takashi, additional, Kanmura, Shuji, additional, Karakina, Marina, additional, Katsuhiko, Nakai, additional, Kierkus, Jaroslaw, additional, Kim, Hyo Jong, additional, Kim, Tae-Oh, additional, Kim, Young-Ho, additional, Kiss, Gyula G., additional, Klaus, Jochen, additional, Kleczkowski, Dariusz, additional, Klopocka, Maria, additional, Kobayashi, Taku, additional, Kobielusz-Gembala, Iwona, additional, Koo, Ja Seol, additional, Kopon, Adam, additional, Kravchenko, Tetiana, additional, Kudo, Masatoshi, additional, Kwon, Kwang An, additional, Lago, Paula, additional, Laharie, David, additional, Lawrance, Ian, additional, Leszczyszyn, Jaroslaw, additional, Li, Yan, additional, Lukas, Milan, additional, Maaser, Christian, additional, Maemoto, Atsuo, additional, Marusawa, Hiroyuki, additional, McBride, Matthew, additional, Mendu, Shoba, additional, Miheller, Pal, additional, Miyabayashi, Hideharu, additional, Mohl, Wolfgang, additional, Moore, Gregory, additional, Motoya, Satoshi, additional, Murali, Narayanachar, additional, Naem, Mohammed, additional, Nakajima, Koichi, additional, Nakamoto, Yasunari, additional, Nancey, Stéphane, additional, Neto, Joaquim, additional, Onizawa, Michio, additional, Ono, Yohei, additional, Osada, Taro, additional, Osipenko, Marina, additional, Owczarek, Danuta, additional, Patel, Bhaktasharan, additional, Patel, Kamal, additional, Petrova, Elina, additional, Poroshina, Elena, additional, Portela, Francisco, additional, Prystupa, Lyudmyla, additional, Rivero, Monserrat, additional, Roblin, Xavier, additional, Romatowski, Jacek, additional, Rydzewska, Grazyna, additional, Saibeni, Simone, additional, Sakuraba, Hirotake, additional, Samaan, Mark, additional, Schultz, Michael, additional, Schulze, Joerg, additional, Sedghi, Shahriar, additional, Seidler, Ursula, additional, Shin, Sung Jae, additional, Stanislavchuk, Mykola, additional, Stokesberry, David, additional, Suzuki, Takayoshi, additional, Taguchi, Hiroki, additional, Tankova, Lyudmila, additional, Thin, Lena, additional, Tkachev, Alexander, additional, Torrealba, Leyanira, additional, Tsarynna, Nataliia, additional, Tulassay, Zsolt, additional, Ueo, Tetsuya, additional, Valuyskikh, Ekaterina, additional, Vasilevskaya, Olga, additional, Viamonte, Manuel, additional, Wei, Shu-Chen, additional, Weisshof, Roni, additional, Wojcik, Katarzyna, additional, Ye, Byong Duk, additional, Yen, Hsu-Heng, additional, Yoon, Hyuk, additional, Yoshida, Kosuke, additional, Yurkiv, Andriy, additional, Zaha, Osamu, additional, and Zhan, Qiang, additional

Published
2023
Full Text
View/download PDF

50. Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies

Author

Gao, Xiang, primary, Fujii, Toshimitsu, additional, Ye, Byong Duk, additional, Chou, Jen‐Wei, additional, Sugimoto, Ken, additional, Cao, Qian, additional, Kligys, Kristina, additional, Murakoshi, Kaoru, additional, Teng, Dennis, additional, Zhang, Yafei, additional, and Nakase, Hiroshi, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results